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Proteinase-activated receptor-2 (PAR2), is a member of the G-
protein coupled receptor (GPCR) subfamily typiﬁed by the thrombin
receptor, PAR1 [1]. The receptor is activated by serine proteinases,
most notably trypsin and tryptase [2–4]. Extensive study of PAR2 has
revealed the receptor to be of potential importance in the functional
control of blood vessel function [5,6], lung patency [7] and
gastrointestinal tract motility and ion transport. A number of
additional studies have implicated a role for PAR2 in several diseasestates including chronic arthritis, inﬂammatory pain and colitis [8–10]
and in skin disorders such as type IV and contact dermatitis [11,12].
However, additional evidence also supports an anti-inﬂammatory
role, for example PAR2 mediates PGI2-dependent relaxation of vessels
which counteracts pro-inﬂammatory events such as ischaemia–
reperfusion injury [13], and in the airways, PAR2 activation evokes
an epithelium and prostanoid-dependent relaxation in isolated
bronchi from several species [14]. What molecular mechanisms
mediate such duality of function is unknown.
The cellular actions of PAR2 have been shown to be mediated
through the activation of a number of key signalling pathways. This
includes the mitogen-activated protein kinases, principally ERKs [15]
mediated via interactionwith the beta arrestins [16]. PAR2 also couples
to a number of signalling pathways usually stimulated strongly by
cytokines, such as the nuclear factor kappa B (NFκB) pathway and the
stress-activated protein kinases, p38map kinase and JNK [17,18]. PAR2
coupling to the stress-activated protein kinases, JNK, and p38 MAP
kinase has been demonstrated in transfected cells [17], human blood
eosinophils, and rat pancreatic stellate cells [19,20], however the exact
mechanisms involved remain unclear.
Previous studies have demonstrated that activation of PAR2 leads to
the release of several potent pro-inﬂammatory mediators, including IL-
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responses. TNFα pre-treatment has been shown to up-regulate
functional PAR2 in endothelial cells [24,25], whilst recent studies have
shownPAR2 to interactwith TLR-4 signalling viamyd88 [26], suggesting
the potential for PAR2 to enhance inﬂammation. Thus, in this study we
examined the potential for PAR2 to synergize with TNFα in the
activation of pro-inﬂammatory signalling responses such as JNK and
p38MAP kinase in a cell line (clone G) expressing both PAR2 and TNFR1
receptors. However to our surprisewe found that activation of PAR2was
associated with a marked inhibition in TNFα stimulated JNK phosphor-
ylation and to a lesser extent NFκBwhichwasmediated by activation of
theGq/11 pathway via the activation of PKC andhad a site of inhibition at
the coupling of TNFR1 to receptor associated proteins. This extends a
previous study fromour laboratory examining purinergic P2Y receptors
and suggests the existence of a novel paradigm for GPCR signalling, the
inhibition of TNFα-stimulated JNK.
2 . Material and methods
2.1. Reagents
All materials used were of the highest commercial grade available
and were purchased from Sigma (Dorset, UK) or Calbiochem (Notting-
ham, UK), unless otherwise stated. The PKC inhibitor, GF109203X, was
obtained from Calbiochem (San Diego, CA, USA). Antibodies raised
against phosphorylated forms of JNK and p38 MAP kinase were
purchased from Biosource (CA, USA). Anti-IκBα, anti-JNK and p38
MAP kinase antibodies were obtained from Santa Cruz Biotechnology
(CA, USA).Meanwhile, tumour necrosis factor-α (TNFα)waspurchased
from Insight Biotechnology (Middlesex, UK). The PAR2 activating
peptide 2f-LIGKV-OH and the novel PAR2 peptide mimetic K-14585
were kind gifts from the Kowa Company Ltd. (Tokyo, Japan). The YM-
254890 compound was a kind gift of Astellas Pharma. Inc, Japan.
2.2. Cell culture
Human skin epithelial cells NCTC2544 were maintained in M199
medium with Earl's salt supplement, 10% (v/v) foetal calf serum, L-
glutamine (27 µg/ml), penicillin (250 U/ml), and streptomycin (25 mg/
ml). NCTC2544 cells stably expressing human PAR2 (clone G) were
maintained in complete M199 medium containing 400 μg/ml of
Geneticin for selection pressure and passaged using Versene (2%
EDTA/PBS). EAhy-926 cells were produced by hybridizing human
umbilical vein endothelial cells (HUVECs) with the epithelial cell line
A549 [27] and maintained in Dulbecco's Modiﬁed Eagle's Medium
(DMEM) supplemented with 10% foetal calf serum (FCS), hypoxan-
thine/aminopterin/thymidine (HAT supplement), penicillin (250 U/ml)
and streptomycin (25 mg/ml), and cells were passaged using Versene.
HUVECs were grown in endothelial basal media, supplemented
with endothelial growth media (EGM-2) containing single aliquots
(2% foetal bovine serum, 0.2 ml hydrocortisone, 2 ml hFGF-B, 0.5 ml
VEGF, 0.5 ml R3-insulin like growth factor-1, 0.5 ml ascorbic acid,
0.5 ml hEGF, 0.5 ml GA 1000, and 0.5 ml heparin) purchased from
Cambrex. All experiments were performed between passages 3 and 7.
All cells were kept in a humidiﬁed atmosphere containing 5% CO2 at
37 °C.
2.3. Western blotting
Proteins were separated by 10% SDS–PAGE and transferred onto
nitrocellulose. The membranes were blocked for non-speciﬁc binding
for 2 h in 2% BSA (w/v) diluted in NATT buffer (50 mM Tris–HCl,
150 mM NaCl, 0.2% (v/v) Tween-20). The blots were then incubated
overnight with 50 ng/ml primary antibody diluted in 0.2% BSA (w/v)
in NATT buffer. The blots were washed with NATT buffer for 90 min
and incubated with HRP-conjugated secondary antibody (20 ng/ml in0.2% BSA (w/v) diluted in NATT buffer) for 2 h. After a further 90 min
wash, the blots were subjected to ECL reagent and exposed to Kodak
X-ray ﬁlm.
2.4. Immuno-precipitation
For immuno-precipitation of TNFR1, equal amounts of pre-cleared
cell lysates were incubated in Tris–HCl buffer, pH 7.4, containing
50mMNaCl, 1 mMEDTA, 1 mMEGTA, 1% (w/v) TritonX-100, and 0.5%
(w/v) Nonidet P-40, with 2 μg TNFR1 antibody, pre-coupled to protein
G, for 3 h. Lysates were recovered by sequential washes in solubilisa-
tion buffer and in the samebuffer lacking detergents. Precipitateswere
assessed for TRADD or RIP content using Western blotting.
2.5. JNK activity assay
To measure JNK activity, cells were stimulated as appropriate and
the reaction terminated by rapid aspiration and the addition of ice-
cold PBS. The cells were solubilised in 20 mM HEPES buffer, pH 7.7,
containing 50 mM NaCl, 0.1 mM EDTA, 0.1 mM Na3VO4, 0.1 mM
PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1% (w/v) Triton
X-100. Lysates were clariﬁed by centrifugation for 5 min at
13,000 rpm and equal amounts of protein were incubated with
20 μg of GST-c-Jun-(5–89) immobilized on glutathione-Sepharose at
4 °C for 3 h. Beads were then washed three times in solubilisation
buffer and twice in 25 mMHEPES buffer, pH 7.6, containing 20 mM β-
glycerophosphate, 0.1 mM NaV3O4, and 2 mM dithiothreitol. Precipi-
tates were then incubated with the same buffer containing 25 μM/
0.5 μCi of ATP/[γ-32P] ATP in a ﬁnal volume of 30 µl at 30 °C for 30 min.
The reactions were terminated by the addition of 4× SDS-sample
buffer and aliquots of each sample subjected to electrophoresis on 11%
SDS-polyacrylamide gel electrophoresis. Phosphorylation of GST-c-
Jun was then determined by autoradiography.
2.6. Statistical analysis
Where experimental data is shown as a blot, this represents one of
at least 3 experiments and data represents the mean±s.e.m.
Statistical analysis was by one-way ANOVA with Dunnett's post test
(*P<0.05, **P<0.01).
3. Results
Initiallywe sought to investigate the potential for synergy between
PAR2 and TNFα receptor subtypes by a combination of different pre-
incubation strategies. However no noticeable synergy was observed;
rather when cells were pre-incubated with trypsin for 30 min we
revealed a concentration-dependent inhibition of subsequent TNFα-
stimulated JNK activity, as measured by in vitro c-Jun phosphorylation
(Fig. 1, Panels A and B). This inhibitory effect was mimicked by the
human PAR2 tethered ligand agonist SLIGKV-OH and was reﬂected at
the level of phospho-JNK conﬁrming inhibition of JNKphosphorylation
rather than JNK activity itself (Panel C).
Inhibition of TNFα signalling was pathway speciﬁc (Fig. 2), as no
equivalent inhibition of p38 MAP kinase was observed following
SLIGKV-OH pre-treatment (Panel A) whilst ERK activation in response
to TNFα was negligible in this cell type (data not shown). However,
TNFα-induced loss in IκBα expression, a marker of NFκB activation,
was partially reversed (Fig. 2, Panel B).
We next sought to conﬁrm that PAR2 was indeed required for
tryspin and peptide mediated inhibition of TNFα-mediated JNK
signalling (Fig. 3). Using either parental NCTC2544 or vector expres-
sing cells (not shown) we found no equivalent inhibition of JNK
activity (Panel A) at any concentration of peptide tested. Secondly, we
found that pre-incubation of cells with the novel PAR2 antagonist K-
14585was able to reverse the inhibition of JNKmediated by thehuman
Fig. 1. PAR2 activation mediates inhibition of TNFα-stimulated JNK activity and phosphorylation in PAR2 NCTC2544 cells. PAR2 expressing NCTC2544 cells (clone G) were pre-
incubated with increasing concentrations of trypsin or SLIGKV-OH for 30 min prior to stimulation for a further 30 min with TNFα (+) (10 ng/ml). Samples were assessed for JNK
activity (Panel A) or phospho-JNK levels (Panel C) as outlined in theMethods section. Gels from JNK assays were quantiﬁed (Panel B). Each value represents themean±s.e.m from at
least 4 experiments and data was quantiﬁed by densitometry. ⁎P<0.05, ⁎⁎P<0.01 compared to TNFα alone.
Fig. 2. The effect of SLIGKV-OH upon TNFα-stimulated p38 MAP kinase phosphorylation and IκBα loss. PAR2 expressing NCTC2544 cells (clone G) were pre-incubated with
increasing concentrations of SLIGKV-OH for 30 min prior to stimulation for a further 30 min with TNFα (+) (10 ng/ml). Samples were assessed for phospho-p38MAP kinase activity
(Panel A) or IκBα levels (Panel B) as outlined in the Methods section. Each gel is representative of at least 4 experiments.
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Fig. 3. Inhibition of TNFα-stimulated JNK activity is dependent upon PAR2 activation. In Panel A, parental NCTC2544 cells were pre-incubated with increasing concentrations of
trypsin, 30 min prior to stimulation for a further 30 min with TNFα (+) (10 ng/ml). In Panel B, PAR2 NCTC2544 cells were pre-incubated with 10 μM K14585 for 30 min prior to
addition of SLIGKV-OH (100 μM) for 30 min and stimulation with TNFα. In Panel C, PAR4 expressing cells were incubated with AYPGKF (100 µM) 30 min prior to TNFα stimulation. In
Panel D, HUVECs were treated with either SLIGKV-OH (SLIG) or 50 μM UTP for 30 min prior to TNFα stimulation. Samples were assessed for JNK activity or phospho-JNK content as
outlined in the Methods section. Each gel is representative of at least 3 experiments.
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PAR4 expressed in the same cell typewaswithout effect conﬁrming the
receptor speciﬁcity of the response (Panel C). Panel D illustrates that
this inhibition is a feature of endogenously expressed PAR2, as pre-
treatment of HUVECs with peptide reduced TNFα-stimulated JNK
phosphorylation. Interestingly, P2Y2 stimulation mediated greater
inhibition of TNFα stimulated JNK signalling, suggesting that other
GPCRs exhibit the same phenomenon.
In addition, we further analysed the concentration dependency of
not only SLIGKV-OH but also the substituted peptide 2f-LIGKV-OH
originally identiﬁed by ourselves as a more potent PAR2 agonist [8,28].
Both peptides profoundly inhibited TNFα-stimulated JNK activity in a
concentration-dependent manner with IC50 values of 6 μM (6.24±
1.319 μM) for SLIGKV-OHand approximately 2 μM(1.582±0.3422 μM)
for 2f-LIGKV-OH (Fig. 4, Panel A). This accords well with the potency of
these peptides assessed in a series of assays using the same cell line [28].
However,we also found that thesepeptides alonewere able to stimulate
JNK activity in a concentration-dependent manner (Panel B). For
example, 2f-LIGKV-OH caused a strong activation of JNK with an EC50
value of 2 μM (2.121±0.4041 μM), similar to its ability to inhibit JNK
stimulation in response to TNFα. In contrast, SLIGKV-OH was a less
potent activator of JNK with an EC50 value of approximately 10 μM
(10.12±3.305 μM) in comparison to its ability to inhibit JNK (Panel C).
Moreover, the difference in efﬁcacy was marked, and SLIGKV-OH
behaved as a full agonist in inhibiting TNFα signalling (% inhibi-
tion=93.567±6.882%) but was a partial agonist in stimulating JNK
activity alone (% stimulation=43.950±6.482%).
We then examined thepotential signallingpathwayswhich could be
mediating the inhibitory effects of PAR2. PAR2 is coupled to a number of
signalling pathways via G-protein dependent and independentmechanisms. Initially, we found that we could mimic the inhibitory
effect of PAR2 activationwith PMA and that this effect could be reversed
bymicromolar concentrations of the PKC inhibitor, GF109203X, thereby
implicating the involvement of PKC isoforms (Fig. 5, Panel A). Therefore,
we tested the effect of the PKC inhibitor GF109203X on PAR2 mediated
inhibition of JNK activity and phosphorylation. Pre-incubation with a
maximal concentration (10 μM)of this inhibitor reversed the inhibitory
effect of trypsin and SLIGKV-OH on TNFα-stimulated JNK activation
(Panel B and C) and phosphorylation (Panel D). In contrast, another
inhibitorGo6976whichpreferentially inhibits the classical groupof PKC
isoforms waswithout effect (not shown) suggesting a potential role for
the novel PKC isoforms.
We then examined the role of Gαq/11 in the PAR2 mediated in-
hibitory effect (Fig. 6), using the novel Gαq/11 inhibitor YM254890.
This compound has been used previously in our laboratory and has
been validated elsewhere [29]. In untreated cells, TNFα stimulated JNK
phosphorylation and activity as expected, and thiswas inhibited by the
pre-treatment with SLIGKV-OH. However pre-treatment of the cells
with YM254890 resulted in almost complete abrogation of peptide
mediated inhibition of TNFα stimulated JNK phosphorylation (Panel
A) and activity (Panels B and C). A similar reversalwas also observed in
HUVECs (panel D) although the initial PAR2 mediated inhibition was
less.
We next examined the potential site of inhibitionwithin the TNFα-
mediated cascade. We assessed the potential for PAR2 activation to
disrupt the interaction of TNFR1with a number of associated proteins.
TNFR1 was precipitated and the interaction with other proteins
assessed by Western blotting. In basal conditions binding to TRADD
and RIPwasminimal, however, following stimulationwith TNFα there
was amarked increase in both TRADD and RIP recovery conﬁrming the
Fig. 4. Concentration response effects of PAR2 peptides for activation of JNK and inhibition of TNFα-stimulated JNK. PAR2 expressing NCTC2544 cells (clone G) were incubated with
increasing concentrations of SLIGKV-OH or 2f-LIGKV-OH for 30 min and assayed for JNK activity (Panel B) or stimulated for a further 30 min with TNFα (+) before JNK activity was
assessed (Panel A). Samples were assessed for JNK activity as outlined in theMethods section. Gels from JNK assays were quantiﬁed (Panel C). Each value represents themean±s.e.m
from at least 4 experiments and data was quantiﬁed by densitometry.
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severely disrupted with PAR2 peptide pre-treatment (Fig 7, Panel A).
Using the TNFR1/TRADD interaction as amodelwe pre-incubated cells
with either GF109203X or YM254890 prior to PAR2 activating peptide
pre-treatment. Both agents effectively reversed PAR2 mediated
disruption of TNFα driven TNFR1 and TRADD complex formation
(Panel B).
4. Discussion
This study identiﬁes a novel paradigm for PAR2 inhibition of TNFα-
induced JNK signalling. Our evidence strongly points to a Gq/11 and
PKC-dependent cascade which functions to disrupt TNFR1 dependent
signalling. Signiﬁcantly, this inhibitory phenomenon is a feature of
PAR2 in cells endogenously expressing the receptor and in response to
activation of other GPCRs, namely P2Y2 receptors. Thus, it may have
implications as to the regulatory role of GPCRs in a number of phys-
iological and pathophysiological conditions.
Initially, we sought to assess the potential of synergy between PAR2
activation and other cytokines known to participate in inﬂammation
such as TNFα, IL-1 and LPS through activation of selective TLRs. Indeed
a recent study has demonstrated synergy between PAR2 and TLR-4
through the activation of Myd88 [26], and a synergistic effect between
the PAR-2 and LPS receptor, was also previously demonstrated where
PAR agonists and LPS in combination potentiated the synthesis of IL-8 from airway epithelial cells [30]. Howeverwhile research to date has
shown the possibility of receptor cross talk between the PAR family
members [31] and with other GPCRs such as the epidermal growth
factor receptor (EGFR) [32] few studies have looked at possible
interactions with other receptors, such as cytokine, chemokine and
other inﬂammatory receptors. Since activation of PAR2 exhibits many
features similar to cytokines regarding the activation of inﬂammatory
mediator release, this study sought to characterise the differences and
similarities of the signalling pathways mediated by both PAR2 and
TNFα, and to examine the possibility of synergy between these two
receptors. To our surprise we found that PAR2 activation was able to
strongly mediate an inhibition of TNFα mediated JNK signalling in
response to cellular activation by trypsin suggesting a PAR2 mediated
response. Indeed the inhibitory effect of trypsin was mimicked with
the peptides SLIGKV-OH and 2f-LIGKV-OH, but reversed by a novel
PAR2 antagonist K14858, which we have recently characterised [33].
Our pharmacological studies also revealed the potential for agonist-
mediated signalling in relation to PAR2 and JNK. We have previously
demonstrated that trypsin mediated activation of PAR2 results in an
increase in JNK activity [17] and indeed alone SLIGKV-OH and 2ﬂ-
LIGKV-OHwere able to increase JNK. However, we also found a distinct
proﬁle in the ability of SLIGKV-OH to inhibit TNFαmediated JNK and to
activate JNK alone, it was less potent and efﬁcacious in the latter assay.
Thus,we candiscern twoagonist-mediateddirected eventswhich relate
to the activation of JNK. This type of modality is emerging for GPCRs for
Fig. 5. Pharmacological blockade of protein kinase C reverses PAR2 mediated inhibition of TNFα-stimulated JNK activation. PAR2 expressing NCTC2544 cells (clone G) were pre-
incubated with increasing concentrations of GF109203X (GFX) for 30 min then incubated for a further 30 min with 100 nM PMA (Panel A) or 30 nM trypsin (Panel B) prior to
stimulation for a further 30 min with TNFα(+) (10 ng/ml). Samples were assessed for JNK activity (Panels A and B) or phospho-JNK levels (Panel D) as outlined in the Methods
section. Gels from JNK activity assays were quantiﬁed by densitometry (Panel C). Each value represents the mean±s.e.m from at least 4 experiments. ⁎⁎P<0.01 compared to TNFα
and trypsin stimulated.
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at the level of cAMP accumulation, functions as a partial agonist at the
level of ERK activation [34]. Similar types of dual coupling to ERK and
other intermediates have recently been demonstrated for PAR2 [35,36]
but not due to agonist speciﬁc differences.
Whilst this present study focuses on two agonist effects it is theﬁrst
study to raise this potential when examining JNK activation. This
model was also supported when examining the effect of the novel
PAR2 antagonist K-14585 [33]. Whilst in this present study we show
that K-14585 is able to reverse PAR2 mediated inhibition of TNFα
signalling, we found that at higher concentrations, K14585 alone isable to activate both JNK (not shown) and p38MAP kinase [37]. Taken
together, these ﬁndings indicate two distinct agonist-directed signal-
ling pathways driven by SLIGKV-OH, one dependent upon Gq/11 and
one independent, mediating inhibition and activation of JNK respec-
tively. Studies assessing JNK activation in response to GPCRs are
limited; however, it has been shown that free βγ dimers and Gα12/13
subunits can activate JNK in a Rac1-cdc42 dependent manner [38].
Gα12 can also activate JNK via ASK1, independently of the activation of
Rac1 and cdc42 [39].
We then sought to investigate the possible mechanisms by which
PAR2 mediated inhibition of JNK might occur. Our initial studies
Fig. 6. Gq/11 is essential for PAR2 mediated inhibition of JNK activation by TNFα. PAR2 expressing NCTC2544 cells (Panels A and B) or HUVECs (Panel D) were pre-incubated with
(100 nM— Panel A) increasing concentrations of YM254890 (YM) for 30 min then incubated for a further 30 min with SLIGKV-OH (100 μM) prior to stimulation for a further 30 min
with TNFα (+) (10 ng/ml). Samples were assessed for phospho-JNK levels (Panels A and D) or JNK activity (Panel B) as outlined in the Methods section. Gels from JNK activity assays
were quantiﬁed by densitometry (Panel C). Each value represents the mean±s.e.m from at least 4 experiments. ⁎⁎P<0.01 compared to TNFα and peptide stimulated.
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response since PMA was able to mimic the effect of PAR2 activation,
abolishing both JNK activity and phosphorylation. We found good
reversal of PAR2 mediated inhibition using GF109203X, an inhibitor
known to block both Ca2+-dependent and some novel PKC isoforms
[40–42]. NCTC2544-PAR2 cells were found to express the PKC
isoforms, PKCα, β11, δ, ε and θ. This is typical of a number of
keratinocyte cell types including NHEK and HaCat [43]. Previously, we
have shown that PKCα and PKCδ play a role in regulating NFκB
signalling at the level of both IKK activation and phosphorylation of
p65 NFκB, however equivalent studies here using siRNA for PKCα, ε
and θ have not revealed a speciﬁc isoform to date responsible for JNK
inhibition (not shown). PKC is also implicated in a number of other
PAR2-mediated events including sensitization of the TRPV1 in rats
and mice, and chloride transport in intestinal epithelial cells [44,45]
and this current study extends the role for PKC in PAR2-dependent
signalling events.
Our studies also revealed an important role for Gq/11 in PAR2
mediated inhibition of JNK signalling.Weused thenovelGq/11 inhibitorycompound YM254890 which we have previously shown to be a very
effective inhibitor of trypsin and peptide mediated [3H]IP accumulation
[29]. In the present study we demonstrated complete reversal of PAR2
mediated JNK inhibition. Thus, DAG derived from Gq/11 activation is
likely to drive PKC activation and subsequent inhibition of TNFα
stimulated JNK activity. Previously, we have shown that Gq/11 plays a
positive role in the regulation of PAR2 mediated NFκB phosphorylation
and in DNA reporter activity [29], whilst other groups have clearly
demonstrated PAR2 coupling to NFκB. Thus, these ﬁndings conﬂict with
this present study showing the potential of Gq/11 to play a role in PAR2
mediated inhibition of TNFα stimulated IκBα loss. Interestingly, whilst
wewere able to demonstrate PAR2mediated inhibitionof TNFα induced
IκBα loss this effect was not manifest further downstream, and pre-
treatment of cells with peptide did not inhibit subsequent TNFα-
stimulated NFκB reporter activity. Thus, because of the strong interac-
tionsof PAR2withNFκB [29], theoverall outcomeof PAR2/TNFR1 is a loss
in JNK activation only. We are currently assessing if receptors more
poorly coupled to NFκB, for example P2Y2, can mediate an overall
inhibition of NFκB activation.
Fig. 7. PAR2 mediated TNFR1 adapter protein disruption in PAR2 expressing cells. In
Panel A, cells were pre-treated with peptide (100 μM) or vehicle prior to stimulation
with TNFα (10 ng/ml) for 30 min. Lysates were immuno-precipitated for TNFR1 and
immuno-blotted for TRADD and/or RIP, as outlined in the Methods section. In Panel B
cells were pre-treated with 100 nM YM254890 or 3 μM GF109203X for 30 min prior to
pre-treatment with peptide (100 μM), for 30 min, then incubated for a further 30 min
with TNFα (10 ng/ml). TNFR1 immuno-precipitates were immuno-blotted for TRADD.
Each gel is representative of at least three experiments.
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disruption of TNFR1 binding to a number of associated proteins. Upon
activation TNFR1 associates with a number of proteins including
TRADD, RIP, TRAF2, MADD and FADD [46]. Formation of this complex
at the membrane allows TNFα to mediate an array of different sig-
nalling events, such as induction of apoptosis through the FADD-
caspase arm or activation of MAP kinase and NFκB signalling via
TRAF2. For example, TRAF2 contains a conserved C-terminal region
termed the TRAF domain, which interacts with TRADD and an N-
terminal ring ﬁnger required for signalling the activation of NFκB and
JNK/SAPK [47–49]. The fact that p38 MAP kinase was not inhibited
suggests a point in the pathway upstream of both NFkB and JNK. This
is likely to be at the level of TRAFs or MEKKs such as TAK1 or ASK1,
however this will be difﬁcult to decipher as less is known about TRAF
mediated activation of the p38 MAPK pathway [46]. Two recent
studies have shown the potential of PMA, a PKC activator, to disrupt
TNFR1 binding to these intermediates [42,50], however the study
presented here is the ﬁrst to show that this can be receptor mediated.
Pharmacological experiments also demonstrate that the PAR2/Gq/11/
PKC axis is essential in driving such disruption in response to PAR2. At
this point the exact mechanism mediating disruption is unclear, no
studies to date have identiﬁed any PKC phosphorylation sites within
the TNFR1 complex, and thus it is possible that additional interme-
diate proteins may be involved.
The potential for GPCRs to mediate the inhibition of TNFα-mediated
JNK signalling has clear physiological signiﬁcance. For example, in the
endothelium, activation of PAR2 would be able to reduce the damaging
effects of TNFα during inﬂammation. In other cell types where PAR2 is
expressed inhibition of TNFR1 signalling may be of signiﬁcance in
relation to cancer.5. Conclusions
In conclusion we have demonstrated for the ﬁrst time a novel
mechanism whereby PAR2, a GPCR can disrupt TNFα mediated
activation of the JNK pathway. This will provide valuable informationregarding the role of GPCRs in the context of inﬂammation and other
disease states.
Speciﬁc points:
1. PAR2 mediated inhibition of TNFα activated JNK is via coupling to
the heterotrimeric G-protein, Gq/11.
2. This inhibitory response requires members of the PKC family, and
inhibits TNF activation of JNK by disrupting coupling of accessory
proteins, such as RIP and TRADD to TNFR1.
3. This inhibitory effect is mediated by other Gαq/11 linked GPCRs, in
particular by the P2Y2 receptor.
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